DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
TITLE
DMID Protocol Number:
DMID Funding Mechanism: (eg, grant #, contract #)
Pharmaceutical Support Provided by: (if applicable)
Other Identifying Numbers:
IND Sponsor: (if applicable. Do not include IND number)
Principal Investigator:
DMID Protocol Champion:
DMID Medical Monitor:
DMID Clinical Affairs Specialist:
DMID Regulatory Affairs Specialist: (if applicable)
Draft or Version Number: (Refer to DMID SOP for assigning version numbers)
Day Month Year(Write out the month and use international date format, eg, 23 January 2004)
______________________________________________________________________________________________i
DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
STATEMENT OF COMPLIANCE
______________________________________________________________________________________________ii
DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
SIGNATURE PAGE
The signature below constitutes the approval of this protocol and the attachments, and provides the necessary assurances that this trial will be conducted according to all stipulations of the protocol, including all statements regarding confidentiality, and according to local legal and regulatory requirements and applicable US federal regulations and ICH guidelines.
Site Investigator:
Signed: Date:NameTitle
______________________________________________________________________________________________iii
DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
TABLE OF CONTENTS
PageStatement of Compliance...............................................................................................................iiSignature Page..............................................................................................................................iiiTable of Contents..........................................................................................................................ivList of Abbreviations.....................................................................................................................viiProtocol Summary.........................................................................................................................ix1 Key Roles..............................................................................................................................12 Background Information and Scientific Rationale.................................................................2
2.1 Background Information......................................................................................22.2 Rationale.............................................................................................................22.3 Potential Risks and Benefits...............................................................................2
2.3.1 Potential Risks.........................................................................................22.3.2 Known Potential Benefits........................................................................2
3 Objectives.............................................................................................................................33.1 Study Objectives.................................................................................................33.2 Study Outcome Measures...................................................................................3
3.2.1 Primary Outcome Measures....................................................................33.2.2 Secondary Outcome Measures...............................................................3
4 Study Design.........................................................................................................................44.1 Substudies (if applicable)....................................................................................4
5 Study Enrollment and Withdrawal.........................................................................................55.1 Subject Inclusion Criteria.....................................................................................55.2 Subject Exclusion Criteria...................................................................................55.3 Treatment Assignment Procedures.....................................................................5
5.3.1 Randomization Procedures.....................................................................55.3.2 Masking Procedures................................................................................55.3.3 Reasons for Withdrawal..........................................................................55.3.4 Handling of Withdrawals..........................................................................55.3.5 Termination of Study...............................................................................5
6 Study Intervention/Investigational Product............................................................................66.1 Study Product Description...................................................................................6
6.1.1 Acquisition...............................................................................................66.1.2 Formulation, Packaging, and Labeling....................................................66.1.3 Product Storage and Stability..................................................................6
6.2 Dosage, Preparation and Administration of Study Intervention/Investigational Product................................................................................................................6
6.3 Modification of Study Intervention/Investigational Product for a Participant.......66.4 Accountability Procedures for the Study Intervention/Investigational Product(s)66.5 Assessment of Subject Compliance with Study Intervention/Investigational
Product................................................................................................................6______________________________________________________________________________________________
iv
DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
6.6 Concomitant Medications/Treatments.................................................................77 Study Schedule.....................................................................................................................8
7.1 Screening............................................................................................................87.2 Enrollment/Baseline............................................................................................87.3 Follow-up.............................................................................................................87.4 Final Study Visit...................................................................................................87.5 Early Termination Visit........................................................................................87.6 Unscheduled Visit................................................................................................8
8 Study Procedures/Evaluations..............................................................................................98.1 Clinical Evaluations.............................................................................................98.2 Laboratory Evaluations........................................................................................9
8.2.1 Clinical Laboratory Evaluations...............................................................98.2.2 Special Assays or Procedures................................................................98.2.3 Specimen Preparation, Handling, and Shipping......................................9
9 Assessment of Safety.........................................................................................................109.1 Specification of Safety Parameters...................................................................109.2 Methods and Timing for Assessing, Recording, and Analyzing Safety
Parameters........................................................................................................109.2.1 Adverse Events.....................................................................................109.2.2 Reactogenicity (for Vaccine Studies and Some Therapeutic Trials).....109.2.3 Serious Adverse Events........................................................................109.2.4 Procedures to be Followed in the Event of Abnormal Laboratory Test
Values or Abnormal Clinical Findings....................................................109.3 Reporting Procedures.......................................................................................10
9.3.1 Regulatory Reporting for Studies Conducted Under DMID-Sponsored IND........................................................................................................10
9.3.2 Regulatory Reporting for Studies Not Conducted Under DMID-Sponsored IND............................................................................10
9.3.3 Other Adverse Events (if applicable).....................................................119.3.4 Reporting of Pregnancy.........................................................................11
9.4 Type and Duration of Follow-up of Subjects after Adverse Events...................119.5 Halting Rules.....................................................................................................119.6 Safety Oversight (ISM plus SMC or DSMB)......................................................11
10 Clinical Monitoring...............................................................................................................1210.1 Site Monitoring Plan..........................................................................................12
11 Statistical Considerations....................................................................................................1311.1 Study Hypotheses.............................................................................................1311.2 Sample Size Considerations.............................................................................1311.3 Planned Interim Analyses (if applicable)...........................................................13
11.3.1 Safety Review........................................................................................1311.3.2 Immunogenicity or Efficacy Review.......................................................13
11.4 Final Analysis Plan............................................................................................13
______________________________________________________________________________________________v
DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
12 Source Documents and Access to Source Data/Documents.............................................1413 Quality Control and Quality Assurance...............................................................................1514 Ethics/Protection of Human Subjects..................................................................................16
14.1 Ethical Standard................................................................................................1614.2 Institutional Review Board.................................................................................1614.3 Informed Consent Process................................................................................16
14.3.1 Informed Consent/Assent Process (in Case of a Minor).......................1614.4 Exclusion of Women, Minorities, and Children (Special Populations)...............1614.5 Subject Confidentiality.......................................................................................1614.6 Study Discontinuation.......................................................................................1614.7 Future Use of Stored Specimens......................................................................16
15 Data Handling and Record Keeping...................................................................................1715.1 Data Management Responsibilities...................................................................1715.2 Data Capture Methods......................................................................................1715.3 Types of Data....................................................................................................1715.4 Timing/Reports..................................................................................................1715.5 Study Records Retention..................................................................................1715.6 Protocol Deviations...........................................................................................17
16 Publication Policy................................................................................................................1817 Literature References.........................................................................................................19Supplements/Appendices............................................................................................................20Appendix A: Schedule of Events.................................................................................................21
______________________________________________________________________________________________vi
DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
LIST OF ABBREVIATIONS
AE Adverse Event/Adverse ExperienceCFR Code of Federal RegulationsCIOMS Council for International Organizations of Medical SciencesCONSORT Consolidated Standards of Reporting TrialsCFR Code of Federal RegulationsCRF Case Report FormCRO Contract Research OrganizationDCC Data Coordinating CenterDHHS Department of Health and Human ServicesDMID Division of Microbiology and Infectious Diseases, NIAID, NIH,
DHHSDSMB Data and Safety Monitoring BoardeCRF Electronic Case Report FormFDA Food and Drug AdministrationFWA Federalwide AssuranceGCP Good Clinical PracticeHIPAA Health Insurance Portability and Accountability ActIB Investigator’s BrochureICF Informed Consent FormICH International Conference on HarmonisationICMJE International Committee of Medical Journal EditorsIDE Investigational Device ExemptionIEC Independent or Institutional Ethics CommitteeIND Investigational New Drug ApplicationIRB Institutional Review BoardISM Independent Safety MonitorJAMA Journal of the American Medical AssociationMedDRA Medical Dictionary for Regulatory ActivitiesMOP Manual of ProceduresN Number (typically refers to subjects)NCI National Cancer Institute, NIH, DHHSNDA New Drug ApplicationNEJM New England Journal of MedicineNIAID National Institute of Allergy and Infectious Diseases, NIH, DHHSNIH National Institutes of HealthOCRA Office of Clinical Research Affairs, DMID, NIAID, NIH, DHHSOHRP Office for Human Research ProtectionsOHSR Office for Human Subjects ResearchORA Office of Regulatory Affairs, DMID, NIAID, NIH, DHHSPHI Protected Health Information
______________________________________________________________________________________________vii
DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
PI Principal InvestigatorPK PharmacokineticsQA Quality AssuranceQC Quality ControlSAE Serious Adverse Event/Serious Adverse ExperienceSMC Safety Monitoring CommitteeSOP Standard Operating ProcedureUS United StatesWHO World Health Organization
Please modify list to include your protocol-specific terms.
______________________________________________________________________________________________viii
DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
PROTOCOL SUMMARY
Title:
Phase:
Population:
Number of Sites:
Study Duration:
Subject Participation Duration:
Description of Agent or Intervention:
Objectives: Primary:
Secondary:
Description of Study Design:
Estimated Time to Complete Enrollment:
______________________________________________________________________________________________ix
DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
Schematic of Study Design:
______________________________________________________________________________________________x
DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
1 KEY ROLES
Individuals:
Protocol Champion:
Principal Investigator:
Medical Monitor: (if applicable)
Institutions:
Optional:
______________________________________________________________________________________________1
DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
2 BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE
2.1 Background Information
2.2 Rationale
2.3 Potential Risks and Benefits
2.3.1 Potential Risks
2.3.2 Known Potential Benefits
______________________________________________________________________________________________2
DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
3 OBJECTIVES
3.1 Study Objectives
3.2 Study Outcome Measures
3.2.1 Primary Outcome Measures
3.2.2 Secondary Outcome Measures
______________________________________________________________________________________________3
DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
4 STUDY DESIGN
4.1 Substudies (if applicable)
______________________________________________________________________________________________4
DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
5 STUDY ENROLLMENT AND WITHDRAWAL
5.1 Subject Inclusion Criteria
5.2 Subject Exclusion Criteria
5.3 Treatment Assignment Procedures
5.3.1 Randomization Procedures
5.3.2 Masking Procedures
5.3.3 Reasons for Withdrawal
5.3.4 Handling of Withdrawals
5.3.5 Termination of Study
______________________________________________________________________________________________5
DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
6 STUDY INTERVENTION/INVESTIGATIONAL PRODUCT
6.1 Study Product Description
6.1.1 Acquisition
6.1.2 Formulation, Packaging, and Labeling
6.1.3 Product Storage and Stability
6.2 Dosage, Preparation and Administration of Study Intervention/Investigational Product
6.3 Modification of Study Intervention/Investigational Product for a Participant
6.4 Accountability Procedures for the Study Intervention/Investigational Product(s)
6.5 Assessment of Subject Compliance with Study Intervention/Investigational Product
______________________________________________________________________________________________6
DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
6.6 Concomitant Medications/Treatments
______________________________________________________________________________________________7
DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
7 STUDY SCHEDULE
7.1 Screening
7.2 Enrollment/Baseline
7.3 Follow-up
7.4 Final Study Visit
7.5 Early Termination Visit
7.6 Unscheduled Visit
______________________________________________________________________________________________8
DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
8 STUDY PROCEDURES/EVALUATIONS
8.1 Clinical Evaluations
8.2 Laboratory Evaluations
8.2.1 Clinical Laboratory Evaluations
8.2.2 Special Assays or Procedures
8.2.3 Specimen Preparation, Handling, and Shipping
8.2.3.1 Instructions for Specimen Preparation, Handling, and Storage
8.2.3.2 Specimen Shipment
______________________________________________________________________________________________9
DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
9 ASSESSMENT OF SAFETY
9.1 Specification of Safety Parameters
9.2 Methods and Timing for Assessing, Recording, and Analyzing Safety Parameters
9.2.1 Adverse Events
9.2.2 Reactogenicity (for Vaccine Studies and Some Therapeutic Trials)
9.2.3 Serious Adverse Events
9.2.4 Procedures to be Followed in the Event of Abnormal Laboratory Test Values or Abnormal Clinical Findings
9.3 Reporting Procedures
9.3.1 Regulatory Reporting for Studies Conducted Under DMID-Sponsored IND
9.3.2 Regulatory Reporting for Studies Not Conducted Under DMID-Sponsored IND
______________________________________________________________________________________________10
DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
9.3.3 Other Adverse Events (if applicable)
9.3.4 Reporting of Pregnancy
9.4 Type and Duration of Follow-up of Subjects after Adverse Events
9.5 Halting Rules
9.6 Safety Oversight (ISM plus SMC or DSMB)
______________________________________________________________________________________________11
DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
10 CLINICAL MONITORING
10.1 Site Monitoring Plan
______________________________________________________________________________________________12
DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
11 STATISTICAL CONSIDERATIONS
11.1 Study Hypotheses
11.2 Sample Size Considerations
11.3 Planned Interim Analyses (if applicable)
11.3.1 Safety Review
11.3.2 Immunogenicity or Efficacy Review
11.4 Final Analysis Plan
______________________________________________________________________________________________13
DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
12 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS
______________________________________________________________________________________________14
DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
13 QUALITY CONTROL AND QUALITY ASSURANCE
______________________________________________________________________________________________15
DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
14 ETHICS/PROTECTION OF HUMAN SUBJECTS
14.1 Ethical Standard
14.2 Institutional Review Board
14.3 Informed Consent Process
14.3.1 Informed Consent/Assent Process (in Case of a Minor)
14.4 Exclusion of Women, Minorities, and Children (Special Populations)
14.5 Subject Confidentiality
14.6 Study Discontinuation
14.7 Future Use of Stored Specimens
______________________________________________________________________________________________16
DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
15 DATA HANDLING AND RECORD KEEPING
15.1 Data Management Responsibilities
15.2 Data Capture Methods
15.3 Types of Data
15.4 Timing/Reports
15.5 Study Records Retention
15.6 Protocol Deviations
______________________________________________________________________________________________17
DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
16 PUBLICATION POLICY
______________________________________________________________________________________________18
DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
17 LITERATURE REFERENCES
______________________________________________________________________________________________19
DMID Protocol Template Version 2.028 September 2005
______________________________________________________________________________________________
SUPPLEMENTS/APPENDICES
______________________________________________________________________________________________20